Pancreatic cancer clinical trial results released

April 3, 2012

The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

The findings were announced during the American Association for Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago.

"The most important finding is that this approach is feasible and we are encouraged by preliminary evidence that this approach may benefit some patients," said Dr. Ramesh K. Ramanathan, Medical Director of the Virginia G. Piper Cancer Center at Scottsdale Healthcare, a partnership with .

The completed phase II clinical trial: Therapy Selected by Tumor Molecular Profiling in Patients with Previously Treated Metastatic Pancreatic Cancer, is part of a Stand Up To Cancer (SU2C) Pancreatic Cancer Dream Team consortium created in 2009.

Dr. Ramanathan said this is the first clinical study of pancreatic cancer in which biopsies were done of the tumors and treatments were based on the molecular profiling of pancreatic .

The study showed that biopsies could be safely conducted, and that multiple could be identified by IHC and DNA sequencing (Caris Target Now®), CGH and microarray.

"Survival analysis is premature, but we believe some patients have had benefit," Dr. Ramanathan said.

Forty-nine subjects were accrued between August 2010 and January 2012. Fourteen patients did not start protocol therapy either due to insufficient tumor on or due to worsening cancer related symptoms after biopsy. There were 35 evaluable patients.

In most patients — all of whom had prior chemotherapy — molecular profiling at Caris resulted in two or more IHC targets for therapy and a non-cross resistant regimen could be implemented.

The most common IHC targets were topoisomerase 1 or 2 and Thymidylatesynthase. Only commercially available agents were prescribed. Treatment recommendations were based primarily on IHC markers. Common regimens/ agents recommended were FOLFIRI, FOLFOX, irinotecan and doxorubicin.

Study has completed accrual. One patient treated with FOLFIRI is a one-year survivor.

Genomic (CGH and microarray) assays and pathway analysis are ongoing to understand response and molecular factors identified in the cancer cells..

The study's abstract will be presented at an AACR Late-Breaking Poster Session from 8 a.m.-12 p.m. today at Chicago's McCormick Place convention center.

Explore further: Results of new drug for pancreatic cancer patients published

Related Stories

Results of new drug for pancreatic cancer patients published

October 4, 2011
Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new ...

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

July 20, 2011
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation ...

'Seena' clinical trials named for pancreatic cancer advocate

December 1, 2011
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.